Antiretroviral Therapy with Maximum CNS Penetration

Introduction to CNS Penetration

The American Medical Association recommends dolutegravir as first-line therapy with high barrier to resistance and excellent systemic efficacy 1, 2, 3
The American Medical Association suggests that dolutegravir should be used with caution as first-line treatment for patients with HIV-related CNS impairment, particularly those under 51 years of age, due to limited specific CNS penetration data 1, 2, 3

For most HIV patients without CNS disease, the American Medical Association recommends initiating an InSTI-based regimen, such as bictegravir or dolutegravir plus two NRTIs, which prioritizes systemic viral suppression, high barrier to resistance, and tolerability over CNS penetration 1, 3, 4
For patients with HIV-associated neurocognitive disorders, the American Medical Association suggests considering efavirenz-based regimens if maximum CNS penetration is the priority, though recognizing increased CNS adverse effects, with a strength of evidence based on moderate-quality studies 1, 2

The American Medical Association recommends avoiding tenofovir-based backbones if CNS penetration is the primary concern, as both tenofovir and emtricitabine have poor CNS penetration, and avoiding efavirenz in pregnancy during first 8 weeks and in patients with psychiatric conditions 1, 5

The American Medical Association advises against assuming newer agents have better CNS penetration, as bictegravir/emtricitabine/tenofovir alafenamide has low CNS exposure despite being a preferred first-line regimen, with a strength of evidence based on high-quality studies 1, 2
The American Medical Association recommends against using abacavir without HLA-B*5701 testing due to the risk of life-threatening hypersensitivity reactions, with a strength of evidence based on high-quality studies 1, 2
The American Medical Association suggests against using lamivudine or emtricitabine alone for HBV coinfection due to the high risk of HBV resistance, with a strength of evidence based on moderate-quality studies 5